Table 6.
SLE patients (n = 434) | P | Controls (n = 322) | P | |
---|---|---|---|---|
Apolipoprotein B antibodies | ||||
p45 IgM | −0·19 | 0·001 | −0·24 | 0·001 |
MDA-p45 IgM | −0·22 | 0·001 | −0·24 | 0·001 |
p45 IgG | −0·17 | 0·001 | −0·12 | 0·04 |
MDA-p45 IgG | −0·16 | 0·001 | −0·07 | n.s. |
p210 IgM | −0·26 | 0·001 | −0·26 | 0·001 |
MDA-p210 IgM | −0·19 | 0·001 | −0·21 | 0·001 |
p210 IgG | −0·29 | 0·001 | −0·28 | 0·001 |
MDA-p210 IgG | −0·30 | 0·001 | −0·27 | 0·001 |
Apolipoprotein H antibodies | ||||
β2GPI IgM | 0·07 | n.s. | 0·12 | 0·04 |
β2GPI IgG | 0·01 | n.s. | 0·09 | n.s. |
Ig = immunoglobulin; MDA = malondialdehyde; n.s. = not significant.